Vysera, which commenced operations in 2005, is a medical devices company located in Galway, Ireland whose principal activity is the development of products and therapies that can be delivered directly to target sites on the inner surface of the gastrointestinal tract ("GI") via conventional, minimally invasive techniques. The company has a developed unique proprietary biomimetic material technology and is applying this technology to address the significant unmet need for gastrointestinal reflux control (GERD). GERD is a condition in which the contents of the stomach regurgitates (refluxes) into the esophagus. This reflux inflames and damages the lining of the esophagus, leading to complications including asthma, bronchitis and Barretts Esophagus (a pre-cancerous condition). The technology has additional applications in urology, obesity and drug delivery which are in the early stages of development. Vysera's Medical Scientific Advisory Board includes world leading clinicians, located at the Mayo Clinic, Beth Israel Hospital (Harvard Medical School) and Sahlgrenska Hospital in Gothenburg, Sweden. The Medical Scientific Advisory Board provides input and direction to product design, application and associated clinical procedures; with the clinicians providing facilities for extensive testing and product evaluation in a pre-clinical and clinical environment.
